Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/31.CaE0WMJl.js ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Truist Financial analyst Srikripa Devarakonda reiterated a Hold rating on Incyte (INCY – Research Report) today. The company’s shares closed ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...